This study aimed to evaluate the risk of ED associated with GLP-1RA initiation compared with dipeptidyl peptidase-4 inhibitors (DPP4is) in men with T2D.<h4>Methods</h4>We conducted a target trial emulation using electronic health records from a U.S. health system between January 2019 and September 2024. Here, DPP4 is linked to type 2 diabetes mellitus.